All female founded StemSight is curing blindness with stem cells – announces a €500k seed round

StemSight, a Tampere-based startup, is looking to introduce a new treatment  method that can cure severe corneal blindness with an off-the-shelf stem cell therapy. Today,  StemSight is announcing a €500k seed funding round to support the way towards the clinical  trials and market approval.  

The StemSight team has worked on the innovation now for a combined 30 years as part of a  research group from Tampere University. Now they are taking the innovation out from the lab  and bringing it into practise. “Public funding could only get us so far. With the new company  we can truly start to change patients’ lives”, says Koivusalo. 

The members of the founding team have extensive expertise in the field and they have PhDs  from Biotechnology, Genetics, and Cell and Tissue Engineering. The team is also one of a kind  as it’s one of the few all female teams in the Nordic deep tech scene. “While it’s a big step  to start a company, one of the motivations is the possibility of acting as an example for other  women to start their companies and go forward,’’ says Koivusalo.

“There is a huge lack of cornea donor tissue with 12.7 million people worldwide waiting for  a corneal transplant. We can use human stem cells to manufacture new corneal cells in a  scalable way to provide solutions for different types of corneal blindness” 

Laura  Koivusalo, co-founder and CEO of StemSight.